Idogen – Q1 report and update on latest development in the company
Meet Idogens CEO Anders Karlsson the 5th. of May 2022.
Topics for the event:
- Presentation of Q1 report
- Swedish and Norwegian approval for its clinical phase 1/2a study with IDO 8, a completely new type of cell therapy for patients with severe hemophilia A who have developed antibodies to their treatment with coagulation factor VIII.
- What should proceed from latest rights issue be used for?
Idogen develops tolerogenic cell therapies where the goal is to prevent an unwanted activation of the immune system. For patients with hemophilia A, one third of patients develop neutralizing antibodies to the standard treatment and render it inactive. To prevent the body's immune system from attacking such biological drugs, Idogen has developed a patient-specific cell therapy with the intention of creating tolerance for the patient's treatment. The goal is that the patient can thus continue with his vital treatment.
Idogen is listed on NasdaQ First North Growth Market with ticker IDOGEN.
Disclaimer: HC Andersen Capital receives payment from Idogen for a Digital IR/Corporate Visibility subscription agreement.